PURPOSE: DYX1C1 has three alternatively spliced transcripts. Therefore, we expect that alternative transcripts of DYX1C1 are used as a biomarker to detect specific cancer. METHODS: RT-PCR analysis is conducted in order to detect expression of the DYX1C1 gene and the PCR products were analyzed using the Image J program to compare the expression levels of each transcript. RESULTS: We found one of the transcripts was directly associated with an HERV-H LTR element that could be translated into protein sequence. Four new alternative transcripts were identified by RT-PCR analysis with various human tissue samples including 10 normal and adjacent tumor tissue sets. Semi-quantitative RT-PCR analysis showed the transcriptional activity of V3 and V2 was higher in tumor than in normal tissue samples, especially in the colorectal tissue samples. CONCLUSION: Our results indicated that alternatively spliced transcript variants of the DYX1C1 gene could be used as cancer biomarkers to detect colorectal cancer.
PURPOSE:DYX1C1 has three alternatively spliced transcripts. Therefore, we expect that alternative transcripts of DYX1C1 are used as a biomarker to detect specific cancer. METHODS: RT-PCR analysis is conducted in order to detect expression of the DYX1C1 gene and the PCR products were analyzed using the Image J program to compare the expression levels of each transcript. RESULTS: We found one of the transcripts was directly associated with an HERV-H LTR element that could be translated into protein sequence. Four new alternative transcripts were identified by RT-PCR analysis with various human tissue samples including 10 normal and adjacent tumor tissue sets. Semi-quantitative RT-PCR analysis showed the transcriptional activity of V3 and V2 was higher in tumor than in normal tissue samples, especially in the colorectal tissue samples. CONCLUSION: Our results indicated that alternatively spliced transcript variants of the DYX1C1 gene could be used as cancer biomarkers to detect colorectal cancer.
Authors: Y Wang; M Paramasivam; A Thomas; J Bai; N Kaminen-Ahola; J Kere; J Voskuil; G D Rosen; A M Galaburda; J J Loturco Journal: Neuroscience Date: 2006-09-20 Impact factor: 3.590
Authors: A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Tata Nageswara Rao; Jonathan Marks-Bluth; Jessica Sullivan; Manoj K Gupta; Vashe Chandrakanthan; Simon R Fitch; Katrin Ottersbach; Young C Jang; Xianhua Piao; Rohit N Kulkarni; Thomas Serwold; John E Pimanda; Amy J Wagers Journal: Stem Cell Res Date: 2015-02-18 Impact factor: 2.020
Authors: Kristiina Tammimies; Isabel Tapia-Páez; Joëlle Rüegg; Gustaf Rosin; Juha Kere; Jan-Åke Gustafsson; Ivan Nalvarte Journal: Mol Endocrinol Date: 2012-03-01
Authors: Gustaf Rosin; Ulf Hannelius; Linda Lindström; Per Hall; Jonas Bergh; Johan Hartman; Juha Kere Journal: BMC Cancer Date: 2012-02-29 Impact factor: 4.430